Lighthouse Biopharma Consulting, LLC, 39 Emerald Glen Lane, Salem, CT, 06420, USA.
Mol Med. 2024 Aug 13;30(1):122. doi: 10.1186/s10020-024-00840-9.
Current therapy for patients suffering from inflammatory bowel diseases (IBD) is focused on inflammatory mechanisms exclusively and not the dysbiotic microbiota, despite growing evidence implicating a role for intestinal microbes in disease.
Ongoing research into the intestinal microbiota of IBD patients, using new technologies and/or deeper application of existing ones, has identified a number of microorganisms whose properties and behaviors warrant consideration as causative factors in disease. Such studies have implicated both bacteria and fungi in the pathogenesis of disease. Some of these organisms manifest mechanisms that should be amenable to therapeutic intervention via either conventional or novel drug discovery platforms. Of particular note is a deeper characterization of microbial derived proteases and their destructive potential.
Given the steady progress on the mechanistic role of the microbiota in inflammatory diseases, it is reasonable to anticipate a future in which therapeutics targeting microbial derived pathogenic factors play an important role in improving the lives of IBD patients.
目前，炎症性肠病 (IBD) 患者的治疗方法仅专注于炎症机制，而不是针对肠道失调的微生物群，尽管越来越多的证据表明肠道微生物在疾病中起作用。
使用新技术和/或更深入地应用现有技术对 IBD 患者的肠道微生物群进行的持续研究，已经确定了许多微生物，其特性和行为值得考虑作为疾病的致病因素。这些研究表明，细菌和真菌都与疾病的发病机制有关。其中一些生物体表现出的机制应该可以通过传统或新型药物发现平台进行治疗干预。值得特别注意的是，对微生物衍生蛋白酶及其破坏潜力的更深入表征。
鉴于在微生物群在炎症性疾病中的作用的机制方面取得的稳步进展，可以合理地预期，针对微生物衍生的致病因子的治疗方法将在改善 IBD 患者的生活方面发挥重要作用。
